Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01402947 · ClinicalTrials.gov registry record · Phase 1
Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/Mesalamine
A Phase 1 study, sponsored by Shire.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01402947: Completed Phase 1 study, sponsored by Shire.
NCT01402947 is a Phase 1 study that has completed, run by Shire. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01402947, a Phase 1 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a drug interaction study evaluating the pharmacokinetic profiles of Ciprofloxacin XR administered alone \& in combination with MMX Mesalazine/mesalamine.
Primary Outcome
AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.
Interventions
- DRUG Ciprofloxacin XR + MMX Placebo
- DRUG MMX Mesalazine/mesalamine + Ciprofloxacin XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-07-25 |
| Est. Completion | 2011-08-30 |
| Phase | Phase 1 |
What the finished NCT01402947 record still lists
NCT01402947 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 2 interventions - of which Ciprofloxacin XR + MMX Placebo is the first listed.
NCT01402947 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01402947 about?
NCT01402947 is a clinical study titled "Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/Mesalamine". This is a drug interaction study evaluating the pharmacokinetic profiles of Ciprofloxacin XR administered alone \& in combination with MMX Mesalazine/mesalamine.
What is the current status of trial NCT01402947?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2011-07-25. Estimated completion is 2011-08-30.
What interventions are being tested in trial NCT01402947?
The interventions under investigation include: Ciprofloxacin XR + MMX Placebo (DRUG), MMX Mesalazine/mesalamine + Ciprofloxacin XR (DRUG).
Who is sponsoring clinical trial NCT01402947?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01402947's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI